Get started

Healthcare

UNH insider sales flash a warning sign ahead of earningsUnitedHealth Group has had an incredibly strong showing this year, and right now it's priced pretty attractively at oversold level on the hourly chart. On its daily chart it's at RSI 38, nearing oversold (RSI 30) but not quite there yet. It also hasn't yet tested its August low of 220.78 or its one-year lows of 208.07 and 216.84. I suspect we'll get a bounce tomorrow from the hourly oversold level, then fall some more to the 216-220 range. At that point we should be about oversold on the daily chart and should bounce into earnings on October 15. The average analyst price target on UNH is about 299, implying about 33% upside from the current price. Analyst estimates of UNH earnings have held steady for the past month at 3.77, significantly better than 3.41 the same quarter last year. UNH has an 8.7/10 Equity Starmine Summary Score rating. So most signs are bullish. However, company director Richard Burke sold 10,000 shares last week. Other directors also recently sold thousands of shares. All this insider selling doesn't inspire confidence for good earnings this quarter. On that basis alone, I don't think I'd hold this for anything more than a pre-earnings bounce. On the other hand, insider sellers may be responding to political risk rather than to the company's financials. The healthcare sector is expected to report good earnings this quarter, which could make it attractive as a defensive play in an earnings recession. Healthcare is a defensive sector that usually does well when the rest of the market is down. Right now healthcare stocks are cheap, which makes them even more attractive. However, with Elizabeth Warren leading the Democratic pack, UNH's share price may continue its breakdown. Health insurance and pharmaceutical companies are at particular risk from Warren's "Medicare for All" plan, and you may be able to chart healthcare stocks' performance from now until the election as a function of Warren's popularity in the polls.
NYSE:UNH
by ChristopherCarrollSmith
SAVA - Above MA's Possible 15% TargetCassava Sciences, Inc. engages in the development of novel drugs. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX. SHORT INTEREST 1.64M 08/30/19 P/E Current -2.07 P/E Ratio (with extraordinary items) -5.00 Average Recommendation: BUY Average Target Price: 3.00
NASDAQ:SAVALong
by DEXWireNews
CVS attempting rising wedge breakoutCVS has been testing the upper trend line of its rising wedge, which it has breached a couple times in the last two days. The last three days have also seen heavy call option buying activity. CVS has a very bullish 9.4/10 Equity StarMine rating, and it's rated as extremely undervalued by S&P Capital IQ. Investors are betting, in part, that CVS will benefit from the bankruptcy of Fred's, a major competitor. CVS is also now going to be selling a CBD (cannabis) product from SocialCBD. Plus, CVS has big plans to open 50 HealthHUB stores, low-cost clinics that will leverage artificial intelligence as a diagnostic tool. This could help disrupt the cost bubble in the healthcare industry. I don't know that the rising wedge will necessarily break today, but I do think that CVS should see continued strength in the coming year. This is a good long-term buy and hold.
NYSE:CVSLong
by ChristopherCarrollSmith
Gonna Need A Bigger Boat CYHThe biotech sector is known for generating some of the most volatile names around and for good reason. When it comes to biotech and healthcare stocks, innovation is the focus. " Healthcare penny stock Community Health Systems Inc. ( CYH ) is a healthcare company that buys and runs acute care hospitals in the US. The company operates an impressive 103 hospitals across 18 states, holding 17,000 beds. Ever since August 28th, CYH stock has been thriving. It is up over 82% since the 28th going from $1.82 to $3.48." But between the divestiture of assets and this insider buying well below the current share price, what comes next? What catalyst can we look toward now? "From August 27th to August 29th, more than $2 million was spent between Wayne Smith and Benjamin Fordham to pick up more than 1 million shares. The majority of these shares were bought by Smith at an average price between $1.84 and $2.18" 3 Penny Stocks On Robinhood To Watch This Week pennystocks.com
NYSE:CYH
by PennyStocks101
J&J vs opioids (Johnson is winning)Fundamental analysis In one of the first state opioid cases, an Oklahoma judge ruled against Johnson & Johnson, awarding the state $572 million, well below the over $17 billion the state was seeking in damages. Meaning... out of the 17 billion, they lost only 3.36%, and they expect to appeal the case, probably lowering this amount. Technical analysis On a technical analysis, I still think the risk reward ratio is too small to enter a position now. But technicals are good (not great). So I am keeping this on my watchlist.
NYSE:JNJ
by dorfmanmaster
Bullish SharkLeap is looking to make another leap. Harmonic shark patterns leave more room for volatility trades and make for high reward scenario's when traded correctly. As of today (09-04-2019), 84,220 of the 261,828 shares traded where short. This is equivalent to a sizable 32.17% short percent. The technical's are now aligning with some key dates with a potential short squeeze on its way (assuming good data). $LPTX is trading at the lower end of the long-term trading range. Bullish harmonic shark pattern, look for profit taking and/ or chances to add at the 382 and 50 retracement levels to ride up to the top of the range. Not only does this trade have massive upside potential for a swing trade, it is also showing confluence with Fibonacci time-cycles, fib-retracement and trend. Tip of the day: Learning how to be disciplined is vital to trading volatility. Follow our trading team for ideas on how to stay more disciplined in biotech. Disclosure: I have no position in LPTX. I may buy or sell in the next 72 hours. This is not a note to but or sell. Please do your homework before investing.
NASDAQ:LPTXLong
by follow_the_money
Several buy signals on UNHI've been watching UNH closely ever since its big guidance upgrade on the last earnings report. The stock chose that moment to start tanking, and it's been tanking ever since. Hopefully the market has now had enough of this down trend and is ready for the stock to recover. Zacks, one of the best-performing analytics firms, upgraded UNH today to a buy. It's got an 8.3/10 Equity StarMine Summary score. UNH also flashed a buy signal a few days ago on the reverse RSI indicator, and it's in oversold territory on the daily stochastic. There's strong support from volume in the 220-228 range, so this is a good range to buy. Below 220, we could fall to 212 or 200.
NYSE:UNHLong
by ChristopherCarrollSmith
4
DURECT CORP - NASDAQ: $DRRX FlaggingAfter breaking to higher ground a week ago on enormous volume, shares of DURECT CORP - NASDAQ:DRRX finds themselves consolidating the recent thrust in a Flag pattern on lower volume as we can observe from the Daily chart above. In addition, DRRX is now trading above all of its important moving averages 20/50/200 DMA's, which from a technical perspective, is healthy as well as constructive. Both investors/traders may want to continue to monitor the action closely in the days/weeks ahead as we believe that its only a matter of time before the stock comes up-and-out of its Flag with its sights set on greener pastures. Thus, investors/traders may want to put DRRX front-and-center on their radars as we're anticipating a potential move into the $1.40 - $1.60 zone (and potentially higher) should the stock pop out of its pattern within the days/weeks ahead. ****NOTE DURECT Corporation - NASDAQ:DRRX to Announce Second Quarter 2019 Financial Results on August 1, 2019 After Market Close ****
NASDAQ:DRRX
by InsiderFinancial
Harmonic Cypher Final Data from Robarts study coming September, in Spain. To learn more about TAEUS, click here . Company ran by ex-GE executives. TAM is in the Billions of Dollars $$. Low float. Recently broke long-term down trend. Daily, Weekly, Monthly charts #BULLISH. Fibonacci convergence at 618 fib (projection) into September time frame. Follow me on twitter and instagram @ #VolatilityWatch Disclaimer: I am long NDRA. This is not a recommendation to buy or sell. Please do your homework before investing.
NASDAQ:NDRALong
by follow_the_money
Davita - now a BULL trend Technicals analysis WEEKLY Davita broke a downtrend channel, and is now in a consolidation above the 200SMA. (Bull) 50SMA is now crossing above the 200SMA. (Bull) OBV and RSI show divergence, as they have moved in oposite directions since early August. (Short). However... on a daily chart , we see a decent uptrend since early June. Headlines / Fundamental On July 10th: President Donald Trump on Wednesday signed an executive order reimbursing for kidney transplants and reducing the reliance on the costly treatments at dialysis clinics. Analyst fair value target price is $79. Meaning 38% undervalued .
NYSE:DVALong
by dorfmanmaster
Will they name JCPenney JCPenny?J. C. Penney Company, Inc. is an American department store chain with 865 locations. It is a micro-cap @$187million. This upcoming earnings, this companies fate will be decided as the street awaits details of long-term plan. If the stock remains below $1 for a period of 30 consecutive business days, they will face delisting from the NYSE market. JCP August 0.50 straddle is priced for a move of 30% into the expected release of quarterly results before the bell on August 15th. Analyst note: B. Riley FBR lowers their JCP target to $0.60 from $1.30 as they believe that amid traffic/discounting pressure that has been impacting retail in general, there is downside risk to estimates.
J
by dorfmanmaster
QUOTIENT LTD - NASDAQ: $QTNT Works On Its BaseFor the better part of 2019, the shares of QUOTIENT LTD - NASDAQ: QTNT have found themselves range-bound trading within the $8 - $11 zone, while seemingly continuing to build and work on its long drawn base as is evidenced in the Daily chart above. While further work is in order, QTNT remains in decent technical shape as the stock presently finds itself trading above all of its important moving averages 20/50/200 DMA's, which constitutes a healthy technical posture. Additionally, when extending out to both the Weekly and Monthly time-frames, one can also observe that QTNT remains in fine shape as well. Therefore, we have a favorable technical picture across multiple time-frames, which bodes well. Thus, while further work is required, both investors/traders may want to continue to monitor the action closely in the days/weeks ahead for further clues/evidence that things may be about to pick-up. In particular, should QTNT be capable of going topside of the $9.75 level, we may just witness a rapid re-test of the $11 level and perhaps a move into the $12 - $14 zone down the road.
Q
by InsiderFinancial
Bearish Butterfly SGEN has beat biotech averages significantly the past few months and has come to meet my $80 pt which also happens to make a bearish harmonic butterfly pattern. This could have a little more upside as it tests $80-81 but risk/reward would suggest a potential double top that can take this down quite a bit in a short amount of time. If I was short I would be looking to start a position. According to the bearish setup SGEN should find 50 -618 retracement before next ER bringing SGEN down to around the $69 mark. As I have outlined in this setup, SGEN is still making higher lows on long-term chart and after retracing back to $69, should see continue uptrend to ~$84 (assuming another positive ER or catalyst). Tip - Even if you rely mostly on company fundamentals, you should be aware of support/ resistance levels. Please Follow, like, comment, and share so I can continue finding awesome trades. Thank you in advance >+) Find me on Twitter or Instagram @VolatilityWatch Disclosure: I do not own a position in SGEN. I may buy/sell within the next 72 hours. This is not a note to buy or sell, please do your homework before investing.
SShort
by follow_the_money
Corindus Vascular Robotics Inc. - NYSE: $CVRS ConsolidatingTECHNICAL After breaking-out in early Spring (March) and subsequently digesting the move, CVRS broke-out once again last month (May) on enormous volume and now finds itself consolidating in a very constructive manner on lower volume as evidenced in the Daily chart above. With the stock trading just beneath its 20 DMA, yet comfortably above both its 50 and 200 DMA's, the technical picture remains positive, while the recent move into northern territory is absorbed. With that said, it now appears that it is only a matter of time before CVRS embarks on yet another potential leg higher. Thus, both investors/traders may want to continue to monitor the action closely in the days/weeks ahead as the recent consolidation comes to a conclusion with a possible break for greener pastures and a move topside of 3.10 likely triggering its next meaningful advance.
C
by InsiderFinancial
HCA: HCA Healthcare Swing 6/7% (or long term investment)Happy Fourth of July, the most American way to celebrate is profiting off healthcare. HCA Healthcare is the largest publicly traded healthcare system in the United States. Has the scale to swallow non-profits and small scale hospitals across the United States. Limits loss caused by Medicare and Medicaid patients by operating hospitals only in economically sound urban areas. Focused on regions with higher median age such as Florida. Combatting nursing shortage with a majority stake in Galen Nursing College. Lots of debt but high cashflow limits the risk. TA: Weekly MACD Cross Weekly 50ma Fell in April due to UNH earnings concerns (nothing changed fundamentally) Trading within a channel since December Took an initial position April 23rd added more at 135.15. Looking to sell some at 144.00 and hold the rest for long term investment
NYSE:HCALong
by odeaolay
SELECT MEDICAL HOLDINGS CORP - NYSE: $SEM Rounding BottomLast week, SELECT MEDICAL HOLDINGS CORP - NYSE:SEM recaptured its 200 DMA and now finds itself attempting to build on the recent grind into higher ground. In addition, when we examine the action of the Daily chart above, we can also observe that SEM appears to be coming out of a potential rounding bottom. Furthermore, the stock now finds itself trading above all of its important moving averages 20/50/200 DMA's, which is a positive from a technical viewpoint. Thus, both investors/traders may want to continue to monitor the action of SEM in the days/weeks ahead as we believe that it may have eyes initially for the open gap near $17.75, yet more likely, we envision a potential move into the $18 - $20 zone and possibly higher. Nevertheless, SEM displays favorable characteristics across multiple time-frames on the Daily; Weekly; Monthly durations and we suspect that we may just be in the early innings of a move into northern territory. ****NOTE**** SEM will report Earnings on August 1, 2019 before Market Open.
NYSE:SEM
by InsiderFinancial
Choosing an entry on UNHAfter strong earnings and a guidance upgrade, I've just been waiting for an entry point on UNH . Today we are oversold on the hourly RSI and stochastic , and I'm seeing a little bullish divergence coming in on the hourly MACD histogram. We've got support at 254.44 from the 20-day moving average, though there's not a lot of volume located here on the volume profile . I've taken a small long position here, and I'll buy more if we get down closer to 250, where there's more volume and also support from the 50-day and 200-day moving averages.
NYSE:UNHLong
by ChristopherCarrollSmith